Evidence from both comparative and real-world registry analyses supports the role of HeartMate 3™ LVAD in improving outcomes for older advanced heart failure patients.1,2
80.6%
1-Year Survival1
51.1%
5-Year Survival1
The Society of Thoracic Surgeons Intermacs 2025 Annual Report, Focus on Outcomes in Older Adults
Excellent long-term survival in older adults with heart failure¹
HeartMate 3 LVAD survival stratified by age 65 and over
hf-heartmate-3-65+graphs-26
Quality of life gains with an LVAD are dramatic
(at 6 months)¹
>50%
Improvement to NYHA Class I-II from Class IV*
+27 pts
KCCQ (Kansas City Cardiomyopathy Questionnaire)**
+22 pts
EUROQOL Visual Analogue Scale (EQ-VAS)***
Access ongoing clinical insights and resources for improving survival and quality of life for older patients with advanced heart failure.
Transplant waitlist risk redefines outcomes for heart failure patients 65+²
When evaluated from time of listing, HeartMate 3 LVAD survival in real-world patients are similar to that of heart transplant.
72.2%
2-year Event-Free Survival with
Transplant Listing†
76.6%
2-year Event-Free Survival with
HeartMate 3 LVAD†
Survival Outcomes in Middle-aged and Older Patients with Advanced Heart Failure: A Propensity-Matched Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry
Leading with an LVAD may provide earlier benefits for transplant candidates age 65+
- LVAD survival for patients 65+ rivals 2-year event-free survival on the transplant waitlist (~77% vs ~72%)†
- LVADs can bridge the gap for patients who might otherwise decompensate while on the waitlist
What this means:
Clinicians should engage patients in personalized value-based discussions weighing LVAD v. transplant strategies
Search Heart Failure Specialists in Your Area
Clinics are listed in order of geographic proximity from the information entered in the locator. Abbott does not endorse any of the clinics on this locator, but merely provides them as a courtesy to patients. Nor does Abbott represent that this is a full list of clinics in a particular location. The directory is not meant to be an endorsement for any particular clinic. Note that Abbott is a medical device manufacturer and cannot provide medical advice.
For more information about this clinic locator please see our policy. Any information you provide is covered by Abbott’s Privacy Policy.
*83% Class IV at baseline
**Scores from mean 38.6 to 65.4
***Scores from 52 to 74
†Transplant = freedom from death or delisting due to clinical deterioration; HeartMate 3 LVAD = freedom from death
- Nayak A, Cascino TM, DeFilippis EM, et al. The Society of Thoracic Surgeons Intermacs 2025 Annual Report: Focus on Outcomes in Older Adults. Ann Thorac Surg. 2025; https://doi.org/10.1016/j.athoracsur.2025.10.005.
- Uriel N, Sayer GT, Colombo PC, et al. Survival Outcomes in Middle-aged and Older Patients with Advanced Heart Failure: A Propensity-Matched Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry, JACC: Heart Failure (2026), doi: https://doi.org/10.1016/j.jchf.2026.103159
MAT-2676778 v1.0